China Nuokang Bio-Pharmaceutical Inc. priced 4.5 million ADSs early today in their U.S. IPO. Selling shareholders sold an additional half-million ADSs.
China Nuokang is a profitable China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products.
The ADSs are expected to trade on the NASDAQ under the symbol NKBP.
Subscribers can read more via the China Nuokang company profile page.